HTFL
Heartflow, Inc.Company Intelligence Hub
Filing history, signal momentum, and bull/bear evolution
Chronological Filing Evolution (Click to filter / toggle)
Thesis (Bull Case Evolution)
Heartflow is demonstrating a powerful commercial inflection point, characterized by a 41% year-over-year revenue increase to $52.6 million in the first quarter of 2026.…
Antithesis (Bear Case / Structural Risks)
Despite the headline growth, Heartflow continues to struggle with significant operational inefficiencies and a precarious bottom line. The company reported an operating loss of $29.5 million, with a quarterly cash burn of $30.1 million.…
Read the full bull/bear analysis
You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every HTFL filing.
Synthesis (Verdict & Resolution)
The Q1 2026 filing presents a company in a high-stakes transition from a venture-backed startup to a public AI healthcare leader. The fundamental tension lies between impressive top-line momentum and a persistent inability to reach profitability. While the 80% gross margin suggests a highly scalable software model, the ballooning SG&A and R&D expenses indicate that the cost of acquiring and maintaining that growth remains steep. Investors are now weighing the strength of a clean, debt-free balance sheet against the uncertainty of a DOJ investigation and the risk of single-product dependency. The upcoming results of randomized clinical trials and the adoption rate of Plaque Analysis will be the primary determinants of whether Heartflow can convert its technical lead into a sustainable, profitable business model.
Core Takeaway
Heartflow is proving its AI can scale revenue efficiently, but high operating burn and legal risks persist.
Investor Lens
The trade-off is between the high-growth potential of an AI diagnostic monopoly and the risks of a single-product dependency and federal investigation.
Watch Next
Outcome of the DOJ Civil Investigative Demand and enrollment in H2 2026 clinical trials.
Signal Momentum Chart
Quarterly net bull/bear signal ratio. Click nodes to select a quarter.
Signal Timeline
Filing History
The Q1 2026 filing presents a company in a high-stakes transition from a venture-backed startup to a public AI healthcare leader. The fundamental tension lies between impressive top-line momentum and a persistent inability to reach profitability. While the 80% gross margin suggests a highly scalable software model, the ballooning SG&A and R&D expenses indicate that the cost of acquiring and maintaining that growth remains steep. Investors are now weighing the strength of a clean, debt-free balance sheet against the uncertainty of a DOJ investigation and the risk of single-product dependency. The upcoming results of randomized clinical trials and the adoption rate of Plaque Analysis will be the primary determinants of whether Heartflow can convert its technical lead into a sustainable, profitable business model.
Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.